The European Hematology Association (EHA) 2026 conference, held from June 11th to 14th in Stockholm, Sweden, served as a pivotal platform for Johnson & Johnson (J&J) to showcase significant advancements in its multiple myeloma (MM) therapeutic portfolio. The company presented compelling new data for its approved bispecific antibodies, Talvey (talquetamab) and Tecvayli (teclistamab-cqyv), underscoring a strategic redirection of these therapies towards earlier lines of treatment for relapsed or refractory (R/R) multiple myeloma. These presentations, featuring results from pivotal Phase III trials, indicate a potential paradigm shift in the management of this complex blood cancer, with implications for patient outcomes and the evolving MM therapeutics market.
EHA 2026: A Glimpse into the Future of Multiple Myeloma Treatment
The EHA conference is a cornerstone event in the hematology calendar, attracting leading researchers, clinicians, and pharmaceutical innovators worldwide. It serves as a crucial venue for the dissemination of cutting-edge research, the presentation of late-breaking clinical trial data, and the discussion of emerging trends in hematological malignancies. This year’s meeting in Stockholm was particularly notable for the significant emphasis placed on novel therapeutic strategies in multiple myeloma, a disease characterized by its heterogeneity and the persistent need for more effective and durable treatment options. J&J’s substantial presence at EHA 2026, with over 30 abstracts submitted, highlighted its commitment to advancing the care of MM patients. The company’s data presentations focused on its bispecific antibody platforms, Talvey and Tecvayli, aiming to solidify their positions not only in later lines of therapy but, more significantly, in earlier treatment settings.
Market Growth Anticipated Amidst Evolving Treatment Landscape
The therapeutic landscape for R/R multiple myeloma is undergoing rapid transformation, driven by continuous innovation and the introduction of novel drug classes. In anticipation of these advancements, GlobalData, the parent company of Pharmaceutical Technology, projects significant growth in the MM therapeutics market. Their report, "Multiple Myeloma: Eight-Market Drug Forecast and Market Analysis 2022–2032," forecasts the market across eight major economies—the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, and China—to expand substantially, reaching an estimated $29 billion by 2032. This robust growth trajectory is fueled by the increasing prevalence of the disease, improved diagnostic capabilities, and the development of more targeted and effective treatment regimens, including bispecific antibodies and cell therapies. J&J’s strategic push for earlier line utilization of Talvey and Tecvayli directly aligns with this market dynamic, aiming to capture a larger share of this expanding market by offering novel solutions to a broader patient population.
Talvey Combinations Pave the Way for Frontline Utilization
One of the most anticipated presentations at EHA 2026 featured the highly awaited results from the Phase III MonumenTAL-3 trial (NCT05455320). This pivotal study investigated the efficacy of Talvey, J&J’s bispecific antibody targeting CD3 and GPRC5D, in patients with R/R MM who had received at least one prior line of therapy. The trial randomized 864 patients into three arms: Talvey in combination with Darzalex (daratumumab) and pomalidomide (Tal-DP); talquetamab plus daratumumab (Tal-D); and a control arm of daratumumab, pomalidomide, and dexamethasone (DPd). The primary endpoint of the study was progression-free survival (PFS).
The results presented at EHA 2026 demonstrated a profound PFS benefit for both Talvey-containing regimens. After a median follow-up of 24.6 months, and with baseline characteristics found to be balanced across all arms, the hazard ratios (HRs) for progression or death compared to the DPd control arm were remarkably low. The Tal-DP arm showed an HR of 0.28 (95% confidence interval [CI] 0.20–0.40), while the Tal-D arm reported an HR of 0.33 (95% CI 0.24–0.46). Both figures were statistically significant, with p-values less than 0.0001, indicating a substantial reduction in the risk of disease progression.
These impressive HRs translated into significantly higher 24-month PFS rates. The Tal-DP arm achieved an 81.3% PFS rate (95% CI 75.8–85.7), and the Tal-D arm reached 77.6% (95% CI 71.7–82.5). In stark contrast, the DPd control arm reported a 51.2% PFS rate (95% CI 44.8–57.1). Beyond PFS, response endpoints also favored the Talvey combinations. The objective response rate (ORR) was notably higher, standing at 88.2% for Tal-DP and 88.5% for Tal-D, compared to 77.6% for DPd. Furthermore, complete response (CR) or better rates were substantially improved, with 71.1% and 68.9% achieved in the Tal-DP and Tal-D arms, respectively, versus 34.5% in the DPd arm. The depth of response was further underscored by minimal residual disease (MRD)-negative CR rates, which were 52.3% and 46.3% for the Talvey arms, significantly outperforming the 15.9% seen in the DPd arm. Crucially, overall survival (OS) also demonstrated a favorable trend for both Talvey combinations, with HRs of 0.47 (95% CI 0.30–0.73) for Tal-DP and 0.51 (95% CI 0.33–0.78) for Tal-D, suggesting a significant survival benefit.
In terms of safety, adverse events (AEs) associated with Talvey combinations were generally manageable and consistent with the known profiles of the individual agents. The Tal-D doublet, in particular, presented a distinct safety profile alongside comparable efficacy. This potentially allows for the treatment of patients with specific comorbidities or health vulnerabilities that might complicate the use of other multi-drug regimens, further expanding its therapeutic applicability.
J&J’s strategic intention is clear: to leverage these compelling MonumenTAL-3 results to position Talvey for earlier lines of therapy. The company is preparing for US and EU regulatory filings later in 2026, with the aspiration that Talvey could establish a new standard of care as early as the second-line (2L) setting. This ambitious move places Talvey directly into the competitive 2L space, a domain also targeted by J&J’s other bispecific antibody, Tecvayli, through the MajesTEC-3 trial.
MajesTEC-3d Data Refines Tecvayli’s Differentiation in the Treatment Continuum
Complementing the Talvey data, J&J also presented significant findings from the Phase III MajesTEC-3 trial (NCT05083169) concerning Tecvayli, a BCMA-targeted bispecific antibody. This trial evaluated Tecvayli in patients with R/R MM who had received one to three prior lines of therapy. A total of 587 patients were randomized to receive either Tecvayli in combination with daratumumab (Tec-Dara) or daratumumab-based standard regimens, specifically daratumumab-pomalidomide-dexamethasone (DPd) or daratumumab-bortezomib-dexamethasone (DVd).
The MajesTEC-3 trial demonstrated an unprecedented improvement in PFS for the Tec-Dara combination. At a 36-month follow-up, the hazard ratio for PFS was an impressive 0.17, indicating a substantial reduction in the risk of disease progression. The Tec-Dara regimen also outperformed the control arms across all key secondary endpoints, reinforcing its clinical benefit. These results are instrumental in advancing Tecvayli’s potential approval from its prior accelerated FDA approval in fourth-line and later settings, towards a potential standard of care in as early as the second-line treatment setting. Following its FDA approval in March 2026, the Tec-Dara combination has already been recognized by the US National Comprehensive Cancer Network (NCCN) as a category 1 preferred regimen for patients with double refractory myeloma after one prior line of therapy.
The data presented at EHA 2026 specifically aimed to characterize the efficacy of Tec-Dara across various patient subgroups, including those with and without high-risk cytogenetic abnormalities (HRCAs) and functional high-risk (FHR) status. This granular analysis serves to sharpen Tecvayli’s differentiation in an increasingly crowded therapeutic landscape. High-risk cytogenetics and early functional relapse have historically been associated with the most challenging MM patient populations, characterized by poorer outcomes and significant unmet needs. The consistency of Tec-Dara’s efficacy signal across these high-risk subgroups is a meaningful differentiator, potentially underpinning its broader adoption. The data suggests that Tec-Dara may effectively blunt the adverse prognostic impact historically observed in high-risk disease, offering renewed hope for these patients.
However, it is crucial to acknowledge the rapid evolution of the MM treatment landscape. The patient population in the MajesTEC-3 trial was largely anti-CD38-naïve, a scenario that may not fully reflect current real-world clinical practice, where daratumumab-containing quadruplets are increasingly becoming the standard frontline therapy. To address this, J&J is actively investigating Tecvayli in the MajesTEC-9 trial, which is enrolling a population that is largely refractory to anti-CD38 therapies. While MajesTEC-9 assesses Tecvayli as a monotherapy, it aims to provide critical insights into its efficacy in a more heavily pre-treated and anti-CD38-experienced patient cohort.
Tecvayli Demonstrates Remarkable Response in Smoldering Multiple Myeloma
Beyond its application in overt R/R MM, J&J also presented promising data on Tecvayli’s potential role in earlier stages of the disease. Researchers from the Dana-Farber Cancer Institute, in collaboration with J&J, shared findings from the Phase II ImmunoPRISM trial (NCT05469893). This study evaluated Tecvayli in patients diagnosed with high-risk smoldering multiple myeloma (SMM), a pre-malignant stage of MM characterized by an increased risk of progression to active disease.
The ImmunoPRISM trial enrolled 59 patients, who received either Tecvayli as monotherapy (45 patients) or lenalidomide plus dexamethasone (LenDex) (14 patients) for 12 or 24 cycles, respectively. The primary endpoint of the trial was complete response (CR), with secondary endpoints including minimal residual disease (MRD) negativity, PFS, and safety. After a median follow-up of 23.4 months, Tecvayli monotherapy demonstrated a significantly superior clinical benefit compared to the LenDex regimen. The CR rate in the Tecvayli arm was a remarkable 73%, with no CRs observed in the LenDex arm (0%). Furthermore, MRD negativity, a key indicator of deep and durable response, was achieved in 81% of patients treated with Tecvayli, compared to 0% in the LenDex arm.
The two-year PFS rates further highlighted Tecvayli’s efficacy, with 92% of patients in the Tecvayli arm remaining progression-free, versus 51% in the LenDex arm. In terms of safety, cytokine release syndrome (CRS) was observed in 71.1% of patients in the Tecvayli arm, with all events classified as Grade 1 or 2, indicating a manageable safety profile. Rates of Grade 3 or higher adverse events, including neutropenia (36% vs. 79%), thrombocytopenia (4% vs. 14%), and infections (20% vs. 21.4%), were generally lower in the Tecvayli arm compared to the LenDex arm, although specific comparisons for neutropenia showed higher rates in the Tec arm initially. These findings strongly support the potential of Tecvayli as a suitable intervention for patients with high-risk smoldering MM.
The prospect of expanding Tecvayli’s label to include high-risk SMM patients presents a significant commercial opportunity for J&J. If approved for this indication, Tecvayli would become the sole provider of targeted therapies approved for this specific patient population, potentially extending its market reach considerably. Commercially, Tecvayli is already performing well in the multiple myeloma market, with GlobalData’s patient-based forecast projecting global sales to reach $1.85 billion by 2032. The key question remains whether there will be sufficient clinical and payer interest to pursue a label expansion for Tecvayli in the pre-malignant SMM setting, establishing it as a preventative agent.
Broader Implications and Future Directions
The data presented by J&J at EHA 2026 signals a clear strategic intent to position both Talvey and Tecvayli as front-line or early-line treatment options for multiple myeloma. This proactive approach addresses the growing need for more effective and durable therapies in the earlier stages of the disease, where intervention can potentially lead to better long-term outcomes and improved quality of life for patients. The success of these bispecific antibodies in trials like MonumenTAL-3 and MajesTEC-3 not only challenges existing treatment paradigms but also positions J&J at the forefront of the ongoing debates surrounding optimal sequencing of therapies, including CAR-T cell therapies and other bispecific antibodies targeting different antigens.
The sustained investment in bispecific antibody technology, coupled with strategic clinical trial designs aimed at earlier lines of therapy, underscores J&J’s commitment to dominating the MM treatment landscape. As regulatory filings are anticipated for later in 2026, the clinical community will be closely watching to see how these promising data translate into approved indications and, ultimately, into improved patient care. The expanding role of Tecvayli in smoldering myeloma also opens up new avenues for early intervention, potentially altering the natural history of the disease for a significant number of patients. The coming years will undoubtedly be critical in defining the long-term impact of these advancements on the management of multiple myeloma.
